Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.01 AUD
Change Today 0.00 / 0.00%
Volume 0.0
As of 11:31 PM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

agenix ltd (AGX) Snapshot

Open
A$0.01
Previous Close
A$0.01
Day High
A$0.01
Day Low
A$0.01
52 Week High
05/6/15 - A$0.02
52 Week Low
10/8/14 - A$0.01
Market Cap
1.8M
Average Volume 10 Days
142.5K
EPS TTM
A$-0.0039
Shares Outstanding
149.0M
EX-Date
11/16/99
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AGENIX LTD (AGX)

Related News

No related news articles were found.

agenix ltd (AGX) Related Businessweek News

No Related Businessweek News Found

agenix ltd (AGX) Details

Agenix Limited, a biotechnology company, commercializes next generation drugs and diagnostics in Australia. The company commercializes ThromboView, a patented radio-labeled monoclonal antibody, which completed two FDA Phase II human clinical trials for the detection of blood clots in human body. It also commercializes DiagnostIQ, a rapid point-of-care diagnostic platform for a various human health applications. Agenix Limited is based in Melbourne, Australia.

agenix ltd (AGX) Top Compensated Officers

Chief Financial Officer and Company Secretary
Total Annual Compensation: A$130.0K
Manager of New Drug Development - Agenix Biop...
Total Annual Compensation: A$43.8K
Legal Advisor
Total Annual Compensation: A$144.3K
Compensation as of Fiscal Year 2014.

agenix ltd (AGX) Key Developments

Agenix Announces Executive Changes

Agenix Ltd. announced that Mr. Nicholas Weston has resigned as Executive Chairman and Director effective June 1, 2015. Mr. Weston will remain a Director of the Group’s wholly owned China subsidiary, Agenix Biopharmaceutical (Shanghai) Company Limited in order to complete the repatriation of funds from China previously announced. Mr. Weston will continue to assist the company as a trusted and respected legal advisor. Mr. Craig Chapman will act a Non-Executive Chairman. The company announced that Mr. Adam Gallagher has been appointed a Non-Executive Director of the Company and its Australian Subsidiaries. Mr. Gallagher is a Director of Scintilla Strategic Investments Limited, an ASX Microcap investment company. Scintilla is a major shareholder of the Company. Mr. Gallagher is a Director and Company Secretary of Pacific Environment Limited.

Agenix Ltd., Special/Extraordinary Shareholders Meeting, May 12, 2015

Agenix Ltd., Special/Extraordinary Shareholders Meeting, May 12, 2015. Agenda: To consider relation to a settlement of legal proceedings.

Agenix and OKS Settle Writ

Agenix Ltd. has agreed with OKS AGX Inc. to settle the Supreme Court proceedings commenced by OKS. As announced to the market on December 24, OKS commenced proceedings involving claims arising from a $5 million share subscription agreement entered into between Agenix and OKS in March 2008. It made no claims concerning the conduct of any current Agenix board member or personnel. Following discovery of the existence of the writ, which had been issued, but not served, Agenix determined that it was in the best interests of the company that the litigation be settled. The key components of the settlement transaction are as follows: Agenix to provide and maintain OKS with a 10% shareholding in the total issued capital of Agenix for a period of two years or until a point immediately preceding a merger or acquisition transaction by Agenix, whichever occurs first. OKS to be assigned all rights, title and interest in the Thromboview project.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGX:AU A$0.01 AUD 0.00

AGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AGX.
View Industry Companies
 

Industry Analysis

AGX

Industry Average

Valuation AGX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 142.5x
Price/Book 1.4x
Price/Cash Flow 1.9x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AGENIX LTD, please visit www.agenix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.